Cargando…
Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment
BACKGROUND: Pediatric low-grade gliomas (pLGGs) are the most common central nervous system tumor in children, characterized by RAS/MAPK pathway driver alterations. Genomic advances have facilitated the use of molecular targeted therapies, however, their long-term impact on tumor behavior remains cri...
Autores principales: | Tsai, Jessica W, Choi, Jungwhan John, Ouaalam, Hakim, Murillo, Efrain Aguilar, Yeo, Kee Kiat, Vogelzang, Jayne, Sousa, Cecilia, Woods, Jared K, Ligon, Keith L, Warfield, Simon K, Bandopadhayay, Pratiti, Cooney, Tabitha M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011805/ https://www.ncbi.nlm.nih.gov/pubmed/36926246 http://dx.doi.org/10.1093/noajnl/vdac182 |
Ejemplares similares
-
LGG-32. Integrated biologic, radiologic and clinical analysis of pediatric low-grade gliomas during and after targeted therapy treatment
por: Tsai, Jessica W, et al.
Publicado: (2022) -
LGG-03. LONG-TERM FOLLOW UP OF TARGETED THERAPY IN PEDIATRIC LOW-GRADE GLIOMAS: THE DANA-FARBER/BOSTON CHILDREN’S EXPERIENCE
por: Tsai, Jessica, et al.
Publicado: (2021) -
OMRT-6. Optimizing MDM2 inhibition for the treatment of high-grade glioma
por: Rendo, Veronica, et al.
Publicado: (2021) -
LGG-48. The influence of different FGFR1 alterations on pediatric low-grade glioma tumor biology and targeted therapy response
por: Morin, Eric, et al.
Publicado: (2022) -
Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era
por: Manoharan, Neevika, et al.
Publicado: (2022)